140 related articles for article (PubMed ID: 36197659)
1. Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
JAMA Psychiatry; 2022 Dec; 79(12):1173-1179. PubMed ID: 36197659
[TBL] [Abstract][Full Text] [Related]
2. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
4. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries.
Samples H; Nowels MA; Williams AR; Olfson M; Crystal S
Am J Prev Med; 2023 Jul; 65(1):19-29. PubMed ID: 36906496
[TBL] [Abstract][Full Text] [Related]
6. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
[TBL] [Abstract][Full Text] [Related]
7. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
[TBL] [Abstract][Full Text] [Related]
8. Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory models.
Lo-Ciganic WH; Hincapie-Castillo J; Wang T; Ge Y; Jones BL; Huang JL; Chang CY; Wilson DL; Lee JK; Reisfield GM; Kwoh CK; Delcher C; Nguyen KA; Zhou L; Shorr RI; Guo J; Marcum ZA; Harle CA; Park H; Winterstein A; Yang S; Huang PL; Adkins L; Gellad WF
Addiction; 2022 Jul; 117(7):1982-1997. PubMed ID: 35224799
[TBL] [Abstract][Full Text] [Related]
9. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Williams AR; Samples H; Crystal S; Olfson M
Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
[TBL] [Abstract][Full Text] [Related]
10. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Intern Med; 2024 Jun; ():. PubMed ID: 38884975
[TBL] [Abstract][Full Text] [Related]
11. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
Tilhou AS; Dague L; Saloner B; Beemon D; Burns M
JAMA Health Forum; 2022 Mar; 3(3):e220093. PubMed ID: 35977284
[TBL] [Abstract][Full Text] [Related]
12. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
13. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
[TBL] [Abstract][Full Text] [Related]
14. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
Chang HY; Krawczyk N; Schneider KE; Ferris L; Eisenberg M; Richards TM; Lyons BC; Jackson K; Weiner JP; Saloner B
Drug Alcohol Depend; 2019 Aug; 201():127-133. PubMed ID: 31207453
[TBL] [Abstract][Full Text] [Related]
15. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
16. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions.
Lo-Ciganic WH; Huang JL; Zhang HH; Weiss JC; Wu Y; Kwoh CK; Donohue JM; Cochran G; Gordon AJ; Malone DC; Kuza CC; Gellad WF
JAMA Netw Open; 2019 Mar; 2(3):e190968. PubMed ID: 30901048
[TBL] [Abstract][Full Text] [Related]
18. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
19. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
20. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
Mark TL; Parish WJ; Zarkin GA
JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
